BioNTech (BNTX.US) rose nearly 4% to US $139.34 on June 27th. Pfizer Inc (PFE.US) and BioNTech announced that two new vaccines jointly developed will significantly improve the protective effectiveness against Omicron. Preliminary laboratory studies showed that the updated vaccine was also effective against BA.4 and BA.5 strains. One month after vaccination, one dose of monovalent Omicron vaccine (30 μ g and 60 μ g) as booster immunization could increase the geometric mean titer (GMT) of neutralizing antibody by 13.5 and 19.6 times, respectively. A dose of 2-valent Omicron vaccine (30 μ g and 60 μ g) could increase GMT by 9.1 and 10.9 times, respectively. At the same time, both vaccines showed good tolerance to people who had been vaccinated with other Omicron vaccines.